Synthesis of 1,2,4-oxadiazole derivatives: anticancer and 3D QSAR studies

A 3D QSAR study was performed on 1,2,4-oxadiazole derivatives using the [(SW) kNN MFA], CoMFA, and CoMSIA techniques. On the basis of 3D QSAR outcomes, new molecules were designed by substituting different substituents. These designed compounds were synthesized and confirmed their synthesis by spect...

Full description

Saved in:
Bibliographic Details
Published in:Monatshefte für Chemie 2020-03, Vol.151 (3), p.385-395
Main Authors: Vaidya, Ankur, Jain, Shweta, Prashantha Kumar, Br, Singh, Shashank K., Kashaw, Sushil Kumar, Agrawal, Ram Kishore
Format: Article
Language:English
Subjects:
Analytical Chemistry
Anticancer properties
Benzene
Biotechnology
Cancer
Chemistry
Chemistry and Materials Science
Chemistry/Food Science
Colon
Derivatives
Inorganic Chemistry
Organic Chemistry
Original Paper
Oxadiazoles
Physical Chemistry
Prostate
Theoretical and Computational Chemistry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 3D QSAR study was performed on 1,2,4-oxadiazole derivatives using the [(SW) kNN MFA], CoMFA, and CoMSIA techniques. On the basis of 3D QSAR outcomes, new molecules were designed by substituting different substituents. These designed compounds were synthesized and confirmed their synthesis by spectroscopic techniques. The synthesized compounds were screened for their anticancer activity against different cancer cell lines. Compound 2-[3-(pyridine-4-yl)-1,2,4-oxadiazol-5-yl]benzo[ d ]thiazole showed equipotent (IC 50  = 4.96 μM) as 5-fluorouracil (IC 50  = 3.2 μM) against colon (CaCo-2) cancer cell line, and compound [2-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]benzo[ d ]thiazol-4-yl]methanol showed equipotent activity (IC 50  = 0.35 μM) as compared to 5-fluorouracil (IC 50  = 0.23 μM) against colorectal (DLD1) cancer cell line. Compound 2-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]benzo[ d ]thiazole was found to be 4–5 less potent (IC 50  = 19.40 μM) as paclitaxel (IC 50  = 4.10 μM) against breast (T47D) cancer cell line, and compound 4-[5-(benzo[ d ]thiazol-2-yl)-1,2,4-oxadiazol-3-yl]benzene-1,2-diol was found about 10 times less potent (IC 50  = 15.7 μM) than mitomycin (IC 50  = 1.50 μM) against prostate (PC-3) cancer cell line. These results disclose the discovery of new 1,2,4-oxadiazole-based anticancer drugs. Graphic abstract
ISSN:0026-9247
1434-4475
DOI:10.1007/s00706-020-02553-1